

(19) World Intellectual Property Organization International Bureau

(43) International Publication Date 15 March 2001 (15.03.2001)

PCT

(10) International Publication Number WO 01/18038 A3

C12N 15/62, (51) International Patent Classification7: C07K 14/705, A61K 38/17, 38/57, 48/00

- (21) International Application Number: PCT/GB00/03196
- (22) International Filing Date: 18 August 2000 (18.08.2000)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/149,993

20 August 1999 (20.08.1999) US

- (71) Applicant (for all designated States except US): IM-PERIAL COLLEGE INNOVATIONS LIMITED [GB/GB]; Sherfield Building, Imperial College, London SW7 2AZ (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DOLLY, James,

Oliver [IE/GB]; Imperial College of Science, Technology and Medicine, Department of Biochemistry, London SW7 2AY (GB). O'SULLIVAN, Gregory, A. [IE/GB]; Imperial College of Science. Technology and Medicine, Department of Biochemistry, London SW7 2AY (GB). MOHAMMED, Nadiem [GB/GB]; Imperial College of Science, Technology and Medicine, Department of Biochemistry, London SW7 2AY (GB). FORAN, Patrick, G. [GB/GB]; Imperial College of Science, Technology and Medicine, Department of Biochemistry, London SW7 2AY (GB).


- (74) Agent: MILES, John, S.; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,

(57) Abstract:

[Continued on next page]

A method of

(54) Title: ISOFORMS OF SNARE MOLECULES AND THE USES THEREOF IN MODULATION OF CELLULAR EXOCY-TOSIS



treating a patient suffering from poisoning by clostridial toxin a SNARE (soluble wherein (N-ethylmaleimide-sensitive fusion protein)-attachment protein receptor) that is resistant to proteolysis by the said clostridial toxin (toxin-resistant SNARE) and/or is capable of inhibiting the clostridial toxin is supplied to a cell of the patient. The SNARE that is resistant to proteolysis may be, synaptosomal-associated polypeptide of 25 kDA (SNAP-25). SNAP-25 is preferably resistant to proteolysis by BoNT/A, BoNT/E and BoNT/C. A method of treating a patient in need of inhibition of SNARE-dependent exocytosis from a cell capable of SNARE-dependent performing exocytosis wherein a derivative (inhibitory SNARE) that is capable of inhibiting SNARE-dependent

exocytosis is supplied to the said cell of the patient. The inhibitory

SNARE may be a fragment of SNAP-25 that is derivable by cleavage of SNAP-25 by botulinum toxin A (BoNT/A). The cell may be, for example, a nerve cell, adreno-chromaffin cell or insulin-secreting cell. The SNARE may be supplied to the cell by expressing recombinant polynucleotide construct. The SNARE or construct may be targeted to a nerve cell, by means of an inactive clostridial neurotoxin. The SNARE may be expressed under the target cell-specific promoter.

BEST AVAILABLE COPY





NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

17

Published:

- with international search report
- (88) Date of publication of the international search report: 11 October 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

international Application No 68 00/03196

a. classification of subject matter IPC 7 C12N15/62 C07K14/705 A61K38/57 A61K48/00 A61K38/17 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searcheo (classification system followed by classification symbols) C12N C07K A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category * 2-4,6, GONELLE-GISPERT C., HALBAN, P. A., NIEMANN H., PALMER M., CATSICAS S., SADOUL K.: Χ 12-15, 25,30, "SNAP-25a and -25b isoforms are both 32,34, expressed in insulin-secreting cells and can function in insulin secretion." 36-39 BIOCHEMISTRY JOURNAL, vol. 339, 1 April 1999 (1999-04-01), pages 159-165, XP002159203 see page 163 "Production of BoNT/E-resistant SNAP-25 isoforms"; page 159 "Abstract"; p. 162 "Functional role of SNAP-25 isoforms in insulin secretion"; p.160 "Mutagenesis of SNAP-25 isoforms" 1,5, see passages cited above Υ 8-11,16, 26-28, 33,35, 40-45 -/--Patent family members are listed in annex. Further documents are listed in the continuation of box C. X l XI later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. other means document published prior to the international filing date but later than the priority date claimed "3" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 2 3. 04. 01 7 February 2001 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 N! - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl. Celler, J Fax: (+31-70) 340-3016

Form PCT/ISA/210 (second sneet) (July 1992)

13

7

INTERNATIONAL SEARCH REPORT

international Application No is 00/03196

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No.				
Category -	Citation of document, with indication, where appropriate, of the relevant passages			
X	SADOUL K., BERGER A., NIEMANN H., WELLER U., ROCHE P.A., KLIP A., TRIMBLE W.S., REGAZZI R., CATSICAS S., HALBAN P.A:: "SNAP-23 is not cleaved by botulinum neurotoxin E and can replace SNAP-25 in the process of insulin secretion" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 52, 26 December 1997 (1997-12-26), pages 33023-33027, XP002159204 see page 33026 "Discussion"; p. 33024 "SNAP.23 is resistant to cleavage by	2-4,6, 12-15, 25,32,36		
Y	BoNT/E" see passages cited above	1,5,10, 11,16, 26-29, 31,33, 35,44,45		
Y	BRUNSD D., ENGERS S., YANG C., OSSIG R., JEROMIN A., JAHN R.: "Inhibition of transmiter release correlated with the proteolytic activity of tetanus toxin and botulinum toxin A in individual cultured synapsys of Hirudo medicinalis" JOURNAL OF NEUROSCIENCE, vol. 17, no. 6, 15 March 1997 (1997-03-15), pages 1898-1910, XP002159205 see page 1898 "Abstract" and "Introduction"; p. 1902 "Leech SNAP-25 is resistant to cleavage by BoNT/A"; Figure 2B; p.1908 right-hand-side column	1,5, 8-11,16, 29,31, 33,35, 44,45		
Y	WO 95 32738 A (ALERGEN) 7 December 1995 (1995-12-07) cited in the application see page 2 "Summery of the invention"	26-28, 40-43		

7

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)					
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Although claims 1-5, 8-16, 36 and 47 are directed to a method of treatment of					
the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.					
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:					
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)					
This International Searching Authority found multiple inventions in this international application, as follows:					
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.					
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.					
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:					
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:					
1-5(partly), 8-16(partly), 25-39(partly),42-45(partly) and 47(partly)					
Remark on Protest The additional search fees were accompanied by the applicant's protest.					
No protest accompanied the payment of additional search fees.					

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

Ħ

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-5(partly), 8-16(partly), 25-39(partly), 42-45(partly) and 47(partly)

are directed towards forms of SNARE molecules resistant to cleavage by clostridial toxins, their uses and polynucleotides coding therefor.

2. Claims: 1-18(partly), 25-39(partly) and 42-47(partly)

are directed towards forms of SNARE molecules capable of blocking the proteolytic activity of clostridial toxins, their uses and polynucleotides coding therefor

3. Claims: 25-28(partly), 30-39(partly), 42-44(partly) and 46-47(partly)

are directed towards forms of SNARE molecules capable of inhibiting SNARE-mediated exocytosis, their uses and polynucleotides coding therefor.

4. Claims: 26-28(partly), 30(partly), 33-35(partly), 37-39(partly), 40, 41, 42-44(partly) and 47(partly)

are directed towards a gene therapy delivery system based on proteolytically inactive form of clostridial toxin.

INTERNATIONAL SEARCH REPORT

	tion on patent tamily members	Gâ	00/03196
Patent document orted in search report	Publication date	Patent family member(s)	Publication date
WO 9532738	A 07-12-1995	AU 695623 B AU 2622295 A CA 2191754 A DE 69511860 D DE 69511860 T DK 760681 T EP 0760681 A ES 2138740 T JP 10500988 T US 6203794 B	20-08-1998 21-12-1995 07-12-1995 07-10-1999 10-02-2000 27-03-2000 12-03-1997 16-01-2000 27-01-1998 20-03-2001

international Application No

Form PCT//SA/210 (patent family annex) (July 1992)